SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Direxion Shares ETF Trust - Direxion Daily MSCI South Korea Bull 3X ETF

Direxion Daily South Korea Bull 3X Shares

KORU is experiencing extreme volatility and intense community focus as traders react to major structural catalysts, including the upcoming US listing of SK Hynix, a 20-for-1 stock split, and aggressive rebalancing by the South Korean National Pension Service. The stock remains a center of heated debate between bullish retail traders expecting a multi-year AI memory super-cycle and bearish participants concerned about excessive leverage, systemic risk, and the impact of KOSPI-driven technical sell-offs.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending as investors digest the recent Annual General Meeting updates, where leadership emphasized the company's production ramp, a significant cash balance, and the expansion of its customer pipeline into 2026. The stock is seeing heightened volatility as the community debates whether the current price represents a buying opportunity or a technical breakdown, with active discussion focused on the potential for institutional validation from recent 13G filings.

Penguin Solutions, Inc. engages in designing, building, and managing enterprise solutions. It operates through the following segments: Advanced Computing, Integrated Memory, and Optimized LED. The Advanced Computing segment offers platform solutions and services for artificial intelligence, high-performance computing, machine learning, advanced modeling, and the internet of things. The Integrated Memory refers to integrated memory solutions through the design and development. The Optimized LED segment comprises a broad portfolio of application-optimized LEDs. The company was founded in 1988 and is headquartered in Fremont, CA.

Penguin Solutions Inc.

Penguin Solutions is trending due to a powerful combination of strong earnings performance and validation as an NVIDIA AI Factory Specialized Partner. Community sentiment is divided between bulls betting on a multi-year AI infrastructure demand cycle and bears cautioning against potential overextension following the stock's sharp year-to-date gains.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. It will generate domestically produced bitcoin powered by nuclear, hydro, and solar energy. It operates through the Digital Asset Mining and HPC Leasing segments. The company was founded by Paul B. Prager and Nazar M. Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is seeing intense community engagement and high volatility following a massive 20-year infrastructure deal with AI firm Anthropic and subsequent analyst price target upgrades. While bulls are touting the long-term potential of the companys AI data center expansion, the stock is facing significant downward pressure from short-term traders and broader market sector rotations.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

The semiconductor sector is facing increased volatility and profit-taking as investors rotate out of crowded AI-linked positions, fueled by concerns over data center capacity and unsustainable valuation growth. While memory names like Micron remain a focal point for institutional demand, the market is currently navigating a sharp repricing phase that has pressured major chip benchmarks like SMH.

iShares Inc. - iShares MSCI South Korea ETF

iShares MSCI South Korea ETF

The iShares MSCI South Korea ETF is facing heightened volatility and sharp declines as the market reacts to geopolitical tensions and energy supply concerns linked to the conflict in the Middle East. Despite the aggressive sell-off, community discussion remains focused on the long-term outlook for major memory chip leaders like Samsung and SK Hynix, with many investors debating whether to buy the dip or exercise caution amid the broader AI sector's repricing.

Arista Networks, Inc. engages in the development, marketing, and sale of cloud networking solutions. Its solutions include EOS, a set of network applications, and Gigabit Ethernet switching and routing platforms. Its product categories include Core, Cognitive Adjacencies, and Network Software and Services. The company was founded by Andreas Bechtolsheim, David Cheriton, and Kenneth Duda in November 2004 and is headquartered in Santa Clara, CA.

Arista Networks Inc

Arista Networks is trending as investors weigh the company's strong AI infrastructure demand against recent supply chain concerns that triggered a sell-off. While some market participants are wary of valuation premiums and volatility, many remain bullish, viewing the current pullback as a buying opportunity given the critical role of the firm's high-speed networking in expanding data centers.

Roundhill ETF Trust - Roundhill Memory ETF

The DRAM ETF is trending as investors digest a memory sector sell-off, with the community closely tracking the upcoming U.S. Nasdaq listing of SK Hynix and strong Korean memory demand as potential catalysts for a rebound. Discussion is currently polarized, pitting bargain-hunting investors who view recent price drops as a healthy reset against bearish voices concerned about cyclical volatility and over-leveraged market dynamics.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending as the community debates its commercialization timeline, with heightened interest surrounding the upcoming Ducati World Week showcase and the company's strategic move into power systems for AI data centers. Investors remain polarized, with many waiting for manufacturing scale-up news on the Eagle line while others express frustration over the lack of revenue and persistent short interest.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending as investors focus on the upcoming launch of its global Phase 3 AURORA trial in lung cancer and the anticipation of a BLA submission for its prostate cancer program in late 2026. The community is actively discussing the company's valuation relative to its massive addressable market and its potential as a prime M&A target for Big Pharma.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity

Next-generation MDD drugs are driving a new era of innovation, investment, and commercial opportunity   New York, NY – June 30, 2026 – Market News Updates News Commentary – The way Major Depressive Disorder (MDD) is treated is changing faster than it has in years. For decades, most patients relied on traditional antidepressants that often […]
The post Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity appeared first on Financial News Media.

A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year

A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year PR Newswire NEW YORK and TORONTO, June 26, 2026 Issued on behalf of Helus PharmaHelus Pharma...

FNM News Break: Helus Pharma Provides Update on APPROACH Phase 3 Trial Enrollment Progress

– APPROACH Phase 3 clinical trial of HLP003 for the adjunctive treatment of major depressive disorder (“MDD”) is progressing as planned and has surpassed 86% enrollment – – Phase 2 HLP003 data demonstrated long-term efficacy with ~23-point reduction in Montgomery-Asberg Depression Rating Scale (“MADRS”) score compared to baseline at 12 months after two 16 mg […]
The post FNM News Break: Helus Pharma Provides Update on APPROACH Phase 3 Trial Enrollment Progress appeared first on Financial News Media.

Cybin (NASDAQ:HELP) Shares Up 2.7%  - Should You Buy?

Cybin (NASDAQ:HELP) Shares Up 2.7% - Should You Buy...

FDA Fast-Tracks Psychedelic Research After Trump’s Executive Order — CMPS, HELP Stocks Gain

Equity

The FDA stated that this will increase support for psychedelic-based medicines for the treatment of conditions like post-traumatic stress disorder, treatment-resistant depression, and major depressive disorder.

Cybin Inc. (NASDAQ:HELP) Given Average Recommendation of "Buy" by Brokerages

Shares of Cybin Inc. (NASDAQ:HELP - Get Free Report) have been assigned an average recommendation of "Buy" from the six analysts that are covering the firm, Marketbeat Ratings reports. Five analysts...

Cybin (NASDAQ:HELP) Now Covered by TD Cowen

TD Cowen assumed coverage on shares of Cybin in a research report on Monday. They set a "buy" rating and a $8.00 price objective on the stock...

Cybin (NASDAQ:HELP)  Shares Down 2.1%   - Time to Sell?

Cybin (NASDAQ:HELP) Trading Down 2.1% - Here's What Happened...

CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions

CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions PR Newswire VANCOUVER, BC, March 9, 2026 Issued...

HELP Stock Crashes On Anxiety Trial Results, But Here’s Why Jefferies Sees Up To 200% Upside

Jefferies highlighted the Phase 3 Approach trial for depression drug HLP003 as the next key catalyst for the stock.

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$0.86	--	--	N/A
Q4 '25	-$0.83	--	--	N/A
Q3 '25	-$0.76	-$1.00	-31.58%	MISSED

Feed

News

Sentiment

Earnings

Fundamentals

Info

HELPHelus Pharma Inc.

Upcoming Earnings: Q1 '26

Historical Earnings

Latest HELP News